News

Novo Nordisk cuts 2025 outlook and names new CEO on weak Wegovy sales
CNBC's Karen Gilchrist discusses Novo Nordisk's new CEO and the pharma giant's move to cut its full-year guidance on weaker ...
Weight-loss patients taking Zepbound forced to switch to Wegovy after drop in coverage
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
The Patients Forced to Switch From Zepbound to Wegovy
Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...
Drugmaker Novo Nordisk slashes Wegovy sales forecasts, blaming compounding
Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the name-brand medicine. The company says it trying to stop them.
Is your Wegovy real? Here’s how to ID fake weight loss drugs
GoodRx reports on identifying real Wegovy pens, which come in five colors and lack dose selectors. Counterfeits pose health ...
Weight-loss jab Wegovy sees another prescription boost after ban on copycats
Novo Nordisk’s weight loss drug, Wegovy, is experiencing a surge in new prescriptions following a US ban on its copycat ...
Hims & Hers’ ugly split with Wegovy maker weighs on the telehealth company’s future
San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...
New data show most patients now stay on Wegovy, Zepbound after a year
Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S. pharmacy claims.
Forbes Daily: Ozempic And Wegovy Maker Loses Big On Wall Street
Today’s Forbes Daily covers Pacific tsunami activity after powerful quake, Trump breaks with Netanyahu over Gaza, the Forbes 50 Over 50, a railroad merger and more.